Opinion|Videos|July 3, 2024
Evolving Treatment Paradigm and NCCN Guideline Updates
Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.
Advertisement
Episodes in this series
- Dr. Freedland asks Dr. Efstathiou: Please review the current treatment landscape for CSPC. What are the main therapeutic approaches typically utilized for these patients?
- What role does androgen deprivation therapy alone play, and in what settings?
- When are chemotherapy and novel hormonal agents like enzalutamide considered?
- How do you sequence or combine these different modalities in your practice?
- Dr. Efstathiou asks Dr. Freedland:The NCCN guidelines were recently updated to include enzalutamide as a treatment option for high-risk non-metastatic CSPC and metastatic CSPC, as well as metastatic and nonmetastatic CRPC. Can you summarize the significance of these updates?
- How do you see these guideline changes impacting clinical practice patterns?
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
China's NMPA Approves Pirtobrutinib Across CLL
5